Long-term sequelae after immunotherapeutic approaches in haematological malignancies - what do we know?
Mené sur 421 patients pédiatriques atteints d'un lymphome non hodgkinien à cellules B matures à haut risque de récidive (âge moyen : 8,8 ans), cet essai international de phase III évalue l'effet, sur les cellules du système immunitaire, de l'ajout de rituximab à une chimiothérapie intensive
For many decades, chemotherapy has been the cornerstone of successful treatment for paediatric haematological malignancies. The success story of these treatments would not have been possible without improvements in the management of acute toxicities and long-term sequelae. 1 With understanding of the sometimes severe long-term consequences of intensive chemotherapy, the possibility of risk-adapted treatment reduction is a potential option to reduce these side-effects
The Lancet Haematology , commentaire, 2022